PMID- 36316630
OWN - NLM
STAT- MEDLINE
DCOM- 20221102
LR  - 20221104
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 22
IP  - 1
DP  - 2022 Oct 31
TI  - Drug-related adverse events potentially predict the efficacy of apatinib on 
      advanced hepatocellular carcinoma.
PG  - 441
LID - 10.1186/s12876-022-02542-0 [doi]
LID - 441
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is the fourth leading cause of 
      cancer-related deaths worldwide every year, and most HCC patients are diagnosed 
      with advanced disease and can only receive systemic treatment. TKIs are the most 
      important components of the systemic treatment of HCC and have both good efficacy 
      and adverse events (AEs).  METHODS: This analysis included 207 patients with 
      locally advanced unresectable or metastatic HCC who received oral treatment with 
      apatinib. We analyzed the overall survival (OS) and progression-free survival 
      (PFS) of patients with or without corresponding AEs to evaluate which AEs can 
      predict the efficacy of apatinib. RESULTS: Patients with hand-foot syndrome (HFS; 
      p = 0.005), proteinuria (p = 0.006) and diarrhea (p < 0.001) had significantly 
      better OS than those without corresponding AEs, and the appearance of HFS 
      (p = 0.006) and proteinuria (p = 0.004) was associated with longer PFS. 
      CONCLUSION: Among all the AEs induced by apatinib in the treatment of advanced 
      HCC, proteinuria could potentially predict PFS, and diarrhea was a potential 
      predictor of OS.
CI  - (c) 2022. The Author(s).
FAU - Gu, Xiaoying
AU  - Gu X
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China.
FAU - Zhang, Su
AU  - Zhang S
AD  - Department of Gynecologic Oncology, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China.
FAU - Yang, Xuejiao
AU  - Yang X
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China.
AD  - Present Address: Department of Anesthesiology, The Central Hospital of Enshi 
      Tujia and Miao Autonomous Prefecture, 445000, EnshiHubei, China.
FAU - Guan, Tao
AU  - Guan T
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China.
FAU - Hou, Zhenyu
AU  - Hou Z
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China.
FAU - Cao, Manqing
AU  - Cao M
AD  - Department of Breast Surgery, Tianjin's Clinical Research Center for Cancer, Key 
      Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer 
      Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 
      300060, China.
FAU - Li, Huikai
AU  - Li H
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China. tjchlhk@126.com.
FAU - Zhang, Ti
AU  - Zhang T
AD  - Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for 
      Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical 
      University Cancer Institute and Hospital, National Clinical Research Center for 
      Cancer, Tianjin, 300060, China. zhangti@shca.org.cn.
AD  - Present Address: Department of Hepatic Surgery, Fudan University Shanghai Cancer 
      Center, Shanghai Medical College, Fudan University, 200032, Shanghai, People's 
      Republic of China. zhangti@shca.org.cn.
LA  - eng
GR  - 81672884/National Natural Science Foundation of China/
GR  - 2017ZX10203207-004-005/National Major Science and Technology Projects of China/
PT  - Journal Article
DEP - 20221031
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
RN  - 5S371K6132 (apatinib)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - *Antineoplastic Agents/adverse effects
MH  - Treatment Outcome
MH  - Diarrhea/chemically induced
MH  - Proteinuria/chemically induced
PMC - PMC9620633
OTO - NOTNLM
OT  - Adverse Events
OT  - Anti-angiogenesis therapy
OT  - Apatinib
OT  - Hepatocellular Carcinoma
OT  - Prognosis
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/11/02 06:00
MHDA- 2022/11/03 06:00
PMCR- 2022/10/31
CRDT- 2022/11/01 00:42
PHST- 2021/12/16 00:00 [received]
PHST- 2022/10/16 00:00 [accepted]
PHST- 2022/11/01 00:42 [entrez]
PHST- 2022/11/02 06:00 [pubmed]
PHST- 2022/11/03 06:00 [medline]
PHST- 2022/10/31 00:00 [pmc-release]
AID - 10.1186/s12876-022-02542-0 [pii]
AID - 2542 [pii]
AID - 10.1186/s12876-022-02542-0 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2022 Oct 31;22(1):441. doi: 10.1186/s12876-022-02542-0.